Sustained expression of the CFTR gene is a major challenge to gene therapy with either viral or nonviral vectors with immune response to vector and transgene products. One strategy to achieve sustained CFTR expression is to modulate the host immune system through transient immunosuppression. In this study, we examined cyclophosphamide (cytoxan), dexamethasone (Dex), and a combination of cyclosporin, methylprednisolone, and azathioprine (combination) for their effects on long-term expression of the human CFTR delivered with helper-dependent adenoviral vectors in mouse airways. We found that cyclophosphamide significantly enhanced long-term expression of the transgenic human CFTR and the reporter gene LacZ by reducing host immune responses. Dex administration greatly reduced neutralizing antibody production but had no effect on transgene expression. Treatment with a combination of cyclosporin A, azathioprine, and methylprednisolone affected neither CFTR gene expression nor inflammation. Our data suggest that transient immunosuppression might be a strategy to improve sustained expression in gene therapy.
Get full access to this article
View all access options for this article.
References
1.
BarrettPM, AlagelyA, TopolEJ. Cystic fibrosis in an era of genomically guided therapy. Hum Mol Genet, 2012; 21:R66–R71.
2.
LaneMA, DoeSJ. A new era in the treatment of cystic fibrosis. Clin Med, 2014; 14:76–78.
3.
ZeitlinPL. Emerging drug treatments for cystic fibrosis. Expert Opin Emerg Drugs, 2007; 12:329–336.
4.
PabaryR, ThursfieldR, DaviesJC. Highlights of the North American Cystic Fibrosis Conference 2011. J R Soc Med, 2012; 105Suppl 2:S9–S13.
5.
RamseyBW, DaviesJ, McElvaneyNG, et al.A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med, 2011; 365:1663–1672.
6.
WainwrightCE, ElbornJS, RamseyBW, et al.Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med, 2015; 373:1783–1784.
7.
AltonEW, ArmstrongDK, AshbyD, et al.Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med, 2015; 3:684–691.
8.
EmilyXia mAM, HuibiCao, JimHu. Lung gene therapy—how to capture illumination from the light already present in the tunnel. Genes Diseases, 2014; 1:40–52.
9.
FlotteTR, NgP, DyllaDE, et al.Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther, 2007; 15:229–241.
10.
CrystalRG, McElvaneyNG, RosenfeldMA, et al.Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet, 1994; 8:42–51.
11.
KnowlesMR, HohnekerKW, ZhouZ, et al.A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med, 1995; 333:823–831.
12.
ZabnerJ, CoutureLA, GregoryRJ, et al.Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell, 1993; 75:207–216.
13.
HarveyBG, LeopoldPL, HackettNR, et al.Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest, 1999; 104:1245–1255.
ParksRJ, ChenL, AntonM, et al.A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A, 1996; 93:13565–13570.
16.
ToiettaG, KoehlerDR, FinegoldMJ, et al.Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter. Mol Ther, 2003; 7:649–658.
17.
CaoH, MachucaTN, YeungJC, et al.Efficient gene delivery to pig airway epithelia and submucosal glands using helper-dependent adenoviral vectors. Mol Ther Nucleic Acids, 2013; 2:e127.
18.
KoehlerDR, FrndovaH, LeungK, et al.Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med, 2005; 7:1409–1420.
19.
KoehlerDR, SajjanU, ChowYH, et al.Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia. Proc Natl Acad Sci U S A, 2003; 100:15364–15369.
20.
FerrariS, GriesenbachU, GeddesDM, et al.Immunological hurdles to lung gene therapy. Clin Exp Immunol, 2003; 132:1–8.
ChirmuleN, RaperSE, BurklyL, et al.Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions. J Virol, 2000; 74:3345–3352.
23.
CroyleMA, ChirmuleN, ZhangY, et al.“Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol, 2001; 75:4792–4801.
24.
WangZ, StorbR, HalbertCL, et al.Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther, 2012; 20:1501–1507.
25.
CaoH, YangT, LiXF, et al.Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression. Gene Ther, 2010; 18:173–181.
26.
LamS, CaoH, WuJ, et al.Highly efficient retinal gene delivery with helper-dependent adenoviral vectors. Genes Dis, 2014; 1:227–237.
27.
KoehlerDR, MartinB, CoreyM, et al.Readministration of helper-dependent adenovirus to mouse lung. Gene Ther, 2006; 13:773–780.
28.
CaoHB, WangA, MartinB, et al.Down-regulation of IL-8 expression in human airway epithelial cells through helper-dependent adenoviral-mediated RNA interference. Cell Res, 2005; 15:111–119.
29.
CassiviSD, LiuM, BoehlerA, et al.Transplant immunosuppression increases and prolongs transgene expression following adenoviral-mediated transfection of rat lungs. J Heart Lung Transplant, 2000; 19:984–994.
30.
IsoniemiH. Renal allograft immunosuppression. III. Triple therapy versus three different combinations of double drug treatment: two year results in kidney transplant patients. Transpl Int, 1991; 4:31–37.
31.
IsoniemiH, KrogerusL, von WillebrandE, et al.Renal allograft immunosuppression. VI. Triple drug therapy versus immunosuppressive double drug combinations: histopathological findings in renal allografts. Transpl Int, 1991; 4:151–156.
32.
IsoniemiH, TikkanenMJ, AhonenJ, et al.Renal allograft immunosuppression. IV. Comparison of lipid and lipoprotein profiles in blood using double and triple immunosuppressive drug combinations. Transpl Int, 1991; 4:130–135.
33.
CassiviSD, LiuM, BoehlerA, et al.Transgene expression after adenovirus-mediated retransfection of rat lungs is increased and prolonged by transplant immunosuppression. J Thorac Cardiovasc Surg, 1999; 117:1–7.
34.
IwaiT, TomitaY, ShimizuI, et al.Different role of cyclophosphamide-induced tolerance in heart and skin allograft tolerance. Transplant Proc, 2001; 33:173–175.
35.
MianA, GuentherM, FinegoldM, et al.Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors. Mol Genet Metab, 2005; 84:278–288.
36.
O'NealWK, ZhouH, MorralN, et al.Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med, 2000; 6:179–195.
37.
ArrudaVR. The role of immunosuppression in gene- and cell-based treatments for duchenne muscular dystrophy. Mol Ther, 2007; 15:1040–1041.
38.
CaohuyH, JozwikC, PollardHB. Rescue of DeltaF508-CFTR by the SGK1/Nedd4-2 signaling pathway. J Biol Chem, 2009; 284:25241–25253.
39.
ProtaLF, CebotaruL, ChengJ, et al.Dexamethasone regulates CFTR expression in Calu-3 cells with the involvement of chaperones HSP70 and HSP90. PLoS One, 2012; 7:e47405.
40.
SereginSS, AppledornDM, McBrideAJ, et al.Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther, 2009; 17:685–696.
41.
LiuQ, ZaissAK, ColarussoP, et al.The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther, 2003; 14:627–643.
42.
FraiserLH, KanekalS, KehrerJP. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs, 1991; 42:781–795.
43.
LiuLL, JiangY, WangLN, et al.Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs, 2012; 72:1521–1533.
44.
SchwartzSD, RegilloCD, LamBL, et al.Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet, 2015; 385:509–516.
45.
JoungJK, SanderJD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol, 2013; 14:49–55.
46.
WuY, ZhouH, FanX, et al.Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells. Cell Res, 2015; 25:67–79.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
